|
Presented by:
David P. Greenberg, M.D.
Senior Director, Scientific and Medical Affairs
Sanofi Pasteur
Web / Audio Conference
12:15 - 1:15pm - EST
To register and be able to view the presentation, click on following URL:
If necessary, right click on URL and select "open hyperlink"
To hear the presentation, please call:
(800) 230-1093
For technical support during or before the presentation, call (888) 793-6118
Program Objectives
-
Understand that as a result of immunosenescence, persons 65 years of age and older do not respond to influenza vaccines as well as younger adults, and these older individuals suffer disproportionally from influenza-related morbidity and mortality despite relatively high immunization rates
-
Describe the rationale for developing Fluzone High-Dose vaccine and FDA licensure of this vaccine using the Accelerated Approval Process for products intended to meet an unmet medical need for serious and life-threatening diseases
-
Review safety and immunogenicity data from a recent phase III clinical trial, including data demonstrating that Fluzone High-Dose vaccine induces significantly higher antibody responses against all 3 influenza virus strains compared with standard-dose Fluzone vaccine among people 65 years of age and older
Please RSVP by Tuesday June 29th, 2010 to:
Sherry Schilb
In accordance with sanofi pasteur's policies and the PhRMA Code of Interaction with Healthcare Professionals, attendance at this educational program is limited to health-care professionals.
|
